<DOC>
	<DOCNO>NCT00599612</DOCNO>
	<brief_summary>This open label study conduct one site . Six healthy male subject enrolled ensure least four fully evaluable subject . Each subject receive single 10 mg oral dose GW856553 contain 50 microCi [ 14C ] GW856553 . Urine faecal sample collect 216 h dose subject may discharge 168 h 90 % dose recover and/or &lt; 1 % dose excrete 24 h period . Blood plasma collect various sample time dose measure parent drug total drug-related material . Samples urine , faeces plasma transfer separate study characterise quantify metabolite matrix . Safety assess adverse event monitoring , vital sign , ECG clinical laboratory test .</brief_summary>
	<brief_title>To Assess Excretion Balance Pharmacokinetics Single Oral Dose 14CGW856553 Healthy Adult Males</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male age 30 60 year inclusive , time screen . Body weight &gt; / 50 kg ( 110 lb ) . A body mass index ( BMI ) within range 18.5 29.9 kg/m2 inclusive . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction . Any clinically relevant abnormality identify screen medical assessment , laboratory examination , ECG ( 12lead ) . Significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . QTc ( b ) &gt; 450msecs A definite suspect personal family history adverse reaction hypersensitivity trial drug drug similar chemical structure . History regular alcohol consumption exceed average weekly intake &gt; 21 unit ( average daily intake great 3 unit ) . One unit equivalent halfpint ( 284mL ) beer/lager ; 25mL measure spirit 125mL wine ) . Subjects history presence gastrointestinal renal disease condition know interfere absorption , distribution , metabolism excretion drug . Subjects consume grapefruit grapefruit juice within seven day first study day . Subjects exposure three new chemical entity within 12 month prior first dose period . Subjects participate trial different new chemical entity within 90 day prior start study . If participation study result volunteer donate 400mL blood previous 56 day . Subjects receive total body radiation dose great 5.0 mSv ( upper limit WHO category II ) exposure significant radiation ( e.g . serial Xray CT scan , barium meal etc ) 12 month prior study . History elevate blood pressure blood pressure persistently &gt; 140/90 mmHg screening . An unwillingness abstain sexual intercourse pregnant lactating woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , sub dermal implant tubal ligation woman could become pregnant time first dose study medication completion followup procedure . Lack suitability participation study , reason , opinion investigator . Any condition could interfere accurate assessment recovery 14C . Prescribed overthecounter medication within 5 day ( 5 half life , whichever long ) prior first dose day , unless investigator confirm introduce additional risk interfere study procedure outcome . Liver function test ( ALT , AST , ALP , GammaGT bilirubin ) &gt; upper limit normal ( ULN ) screen Positive urine drug screen Positive HIV , Hepatitis B C result screen . History use tobacco nicotinecontaining product within 6 month screen positive urine cotinine screen ( urine cotinine &gt; 250ng/ml ) .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>GW856553 ,</keyword>
	<keyword>radiolabel</keyword>
	<keyword>ADME ,</keyword>
</DOC>